Skip to Content
Merck

M7824

Methotrexate

Synonym(s):

Methotrexate, (+)-Amethopterin, 4-Amino-10-methylfolic acid, 4-Amino-N10-methylpteroyl-L-glutamic acid, Antifolan, MTX, Methylaminopterin

Slide 1 of 1
Sign In to View Organizational & Contract Pricing.

Select a Size

1 G

PLN 9,140.00

5 G

PLN 39,510.00

PLN 9,140.00

Please contact Customer Service for Availability
Request a Bulk Order

About This Item

Empirical Formula (Hill Notation):
C20H22N8O5
CAS Number:
59-05-2
Molecular Weight:
454.44
EC Number:
200-413-8
UNSPSC Code:
41116107
NACRES:
NA.21
Beilstein/REAXYS Number:
70669
MDL number:
MFCD00064370

Key Documents

View All Documentation

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI

1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1

InChI key

FBOZXECLQNJBKD-ZDUSSCGKSA-N

SMILES string

CN(Cc1cnc2nc(N)nc(N)c2n1)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O

biological source

synthetic

form

powder

suitability

suitable for manufacturing use

storage temp.

−20°C

Quality Level

400

Gene Information

human ... DHFR(1719)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
Y0001668Y0000602M9929
Methotrexate

SAFC

M7824

Methotrexate

Methotrexate for system suitability European Pharmacopoeia (EP) Reference Standard

Y0001668

Methotrexate for system suitability

Methotrexate for peak identification European Pharmacopoeia (EP) Reference Standard

Y0000602

Methotrexate for peak identification

Methotrexate meets USP testing specifications

Sigma-Aldrich

M9929

Methotrexate

biological source

synthetic

biological source

-

biological source

-

biological source

synthetic

form

powder

form

-

form

-

form

powder

suitability

suitable for manufacturing use

suitability

-

suitability

-

suitability

-

storage temp.

−20°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

−20°C

Quality Level

400

Quality Level

-

Quality Level

-

Quality Level

400

Gene Information

human ... DHFR(1719)

Gene Information

human ... DHFR(1719)

Gene Information

human ... DHFR(1719)

Gene Information

human ... DHFR(1719), DHFRP1(573971), FPGS(2356), SLC19A1(6573), TYMS(7298)
mouse ... Dhfr(13361)
rat ... Dhfr(24312)

General description

Inhibits thymidylate synthetase, is a nonselective de novo purine synthesis inhibitor and has a significant toxicity profile including hepatotoxicity, pneumonitis and bone marrow suppression. Potent folic acid antagonist. Induces apoptosis in HL-60 human leukemia cells. Also useful as an anti-tumor agent.
Our SAFC® portfolio of high-quality raw materials for use in biopharmaceutical processing withstands strict quality control procedures plus the documentation and expertise to help our customers meet requirements as defined by the M-Clarity Program.

M-Clarity Program

Our comprehensive portfolio of upstream process chemicals not only provides biopharmaceutical manufacturers with high-quality raw materials for production of classical and novel therapies, but also helps them get to market faster and simplify regulatory challenges. Trust us to deliver supply chain transparency and reliable sourcing around the globe, streamlining your product qualification with best-in-class regulatory support and service.

Legal Information

SAFC is a registered trademark of Merck KGaA, Darmstadt, Germany

pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Muta. 2 - Repr. 1B - STOT RE 1

target_organs

Liver,Bone marrow

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000507508
0000507508
0000491173
0000502828
0000502828

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Christian S Kaas et al.
Biotechnology journal, 10(7), 1081-1089 (2015-05-13)
Coagulation factor VIII (FVIII) is one of the most complex biopharmaceuticals due to the large size, poor protein stability and extensive post-translational modifications. As a consequence, efficient production of FVIII in mammalian cells poses a major challenge, with typical yields
Joshua F Baker et al.
Annals of the rheumatic diseases, 73(11), 1968-1974 (2013-08-02)
To determine if early MRI measures predict X-ray progression at 1 and 2 years in a large RA trial cohort. This study included 256 methotrexate (MTX)-naïve RA patients from a randomised placebo-controlled trial of golimumab (GO-BEFORE). MRIs of wrist and 2nd-5th
Roy Fleischmann et al.
Annals of the rheumatic diseases, 74(6), 1132-1137 (2014-08-22)
Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) is used instead of erythrocyte sedimentation rate (DAS28-ESR) to assess rheumatoid arthritis disease activity; however, values for remission and low disease activity (LDA) for DAS28-CRP have not been validated.
Kalle Jyri Aaltonen et al.
The Journal of rheumatology, 42(3), 372-378 (2015-01-17)
Because of the role of tumor necrosis factor (TNF) in host defense, it was hypothesized that its inhibition might lead to an increased risk of malignancies and infections. The objective of our study was to assess the incidence of serious
Anna-Birgitte Aga et al.
Annals of the rheumatic diseases, 74(2), 381-388 (2013-11-29)
To investigate whether baseline disease activity levels and responses in patients with rheumatoid arthritis (RA) changed during the period 2000-2010. Data were provided by the Norwegian disease-modifying antirheumatic drug (NOR-DMARD) study. Patients with inflammatory joint diseases starting new treatment with
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service